Activatable Nucleic Acid Dye for Viable Cell Discrimination

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for detecting viable and non-viable microorganisms, such as those using propidium monoazide (PMA), face limitations in distinguishing between live and dead cells, particularly for certain organisms like Staphylococcus aureus, Mycobacterium avium subspecies paratuberculosis, and Salmonella serovar Enteritidis, due to the dye's ability to penetrate viable cells and fail to accurately quantify viable cells.

Innovation Solution

Development of compounds with a nucleic acid binding dye having an activatable group capable of crosslinking or cleaving target nucleic acids, which selectively labels non-viable organisms or cells by forming a complex with their nucleic acids, allowing for differentiation from viable cells through specific labeling and amplification techniques.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Speed

If PMA treatment is used to distinguish viable and non-viable cells, then detection speed is improved, but measurement precision deteriorates because PMA cannot reliably distinguish between live and dead cells for certain organisms

Engineering Contradiction:
Improvedetection speedVSAvoidviability discrimination accuracy
Core Design Contradiction:
SpeedVSMeasurement precision

Solution Approach 1:

The patent modifies the chemical structure of PMA by introducing a bulky substituent group to create PMA'. This structural parameter change increases the molecular size and steric hindrance, preventing the modified dye from penetrating intact cell membranes of viable cells while still allowing it to bind to and crosslink with DNA from non-viable cells with compromised membranes. This resolves the contradiction by maintaining fast detection speed while improving viability discrimination accuracy.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a dye with non-uniform structure where a large hydrophobic substituent group is attached to the PMA core structure. This local quality change concentrates the binding affinity in specific regions of the molecule while the bulky group provides steric barrier properties. The differentiated local properties enable selective interaction with DNA from dead cells without penetrating live cell membranes, thereby improving measurement precision while maintaining detection speed.

Inventive Principle:
Principle #3Local quality

2Reliability

If PMA is used to label non-viable organisms, then the ability to detect dead cells is improved, but reliability deteriorates because PMA enters viable cells and causes false signals

Engineering Contradiction:
Improvedetection reliability for dead cellsVSAvoidspecificity of labeling
Core Design Contradiction:
ReliabilityVSMeasurement precision

Solution Approach 1:

The patent changes the molecular parameters of PMA by introducing a bulky substituent with specific steric and hydrophobic properties. This parameter modification creates a size and shape mismatch that prevents the modified dye from passing through intact cell membranes of viable cells, while still allowing it to access and bind to exposed DNA from non-viable cells. This resolves the reliability issue by eliminating false labeling of live cells while maintaining accurate detection of dead cells.

Inventive Principle:
Principle #35Parameter changes

3Measurement precision

If conventional PCR is used to amplify nucleic acids, then detection sensitivity is improved, but measurement precision deteriorates because it cannot distinguish between nucleic acid from live and dead cells

Engineering Contradiction:
Improvenucleic acid detection accuracyVSAvoidviability information
Core Design Contradiction:
Measurement precisionVSLoss of information

Solution Approach 1:

The patent applies PMA' treatment to the sample before performing PCR amplification. This preliminary action selectively crosslinks the dye to DNA from non-viable cells, preventing subsequent PCR amplification of that DNA. Viable cell DNA remains unmodified and amplifiable. This preliminary differentiation step preserves viability information that would otherwise be lost during conventional PCR, enabling accurate distinction between live and dead cell nucleic acids.

Inventive Principle:
Principle #10Preliminary action

Solution Approach 2:

The patent uses PMA' to preemptively block or inactivate DNA from non-viable cells before PCR amplification occurs. The dye crosslinks to dead cell DNA, creating a stable complex that cannot serve as a template for polymerase. This preliminary anti-action prevents amplification of irrelevant DNA from dead cells, ensuring that subsequent PCR signals accurately reflect only viable cell populations, thus preventing loss of viability information.

Inventive Principle:
Principle #9Preliminary anti-action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The proposed compounds effectively and selectively label non-viable organisms, reducing PCR amplification signals from dead cells, thereby improving the accuracy in distinguishing between viable and non-viable microorganisms, overcoming the limitations of existing methods.

Implementation Method 1

PMA is a doubly-positively charged DNA binding dye with a photoreactive azido group, which upon photolysis undergoes crosslinking with DNA

Methodology Applied
Scientific EffectPhotolysis: Photodissociation

Implementation Method 2

which upon photolysis undergoes crosslinking with DNA, thereby covalently modifying the nucleic acid with the dye

Methodology Applied
Scientific EffectCrosslinking: Chemical Bonding

Implementation Method 3

PMA is a doubly-positively charged DNA binding dye

Methodology Applied
Scientific EffectElectrostatic interaction: Electrostatics

Data Source

PatentEP3212792B1Nucleic acid modifying agents and uses thereof
Publication Date: 2021.01.06 BIOTIUM INC
  • EP3212792B1 patent drawingFigure 1
  • EP3212792B1 patent drawingFigure 2A~2B
  • EP3212792B1 patent drawingFigure 3A~3D

AI summary

In some aspects, the disclosure provides compounds comprising nucleic acid modifying moieties, such as nucleic acid binding dyes comprising activatable groups. In some aspects, the disclosure provides nucleic acid probes comprising compounds of the disclosure, and methods of making the same. In some aspects, the disclosure provides methods of using compounds of the disclosure, such as methods of labeling and/or detecting non- viable organisms or non- viable cells, and methods of detecting contamination or infection.